What's going on with Race Oncology at the moment ?, page-29

A few things.

1. True market cap for all three pillars works out to be between $400-600 per share. At a discount buy out price of $200, pharma companies would still see this figure as a bargain.

2. All this talk of staying under the radar is all well and good, but it will be very literally impossible after the first major results are published (assuming a positive outcome). Companies will be absolutely privy to these findings and the competitive implications.

3. Trust the board. Please don’t undermine their efforts by shooting down large figures or trying to boost exposure prematurely. It is antithetical to the cause and it really needs to stop. It can really harm potential offers if researchers see that there are people out there willing to settle for X-figure. Let the science and outcomes weigh against the market capitalisation

4. Trust the board.

5. TRUST THE BOARD! Let them continue to do the amazing job they’re doing.

6. For the people at the back - trust the board and listen to their advice when the time comes.